Emergent BioSolutions (EBS) said Monday that the Biomedical Advanced Research and Development Authority executed a contract modification for the second option period, valued at about $16.7 million, for drug product process and analytical testing validation and long-term stability for Ebanga.
Ebanga is indicated for the treatment of infection caused by Zaire Ebola virus.
BARDA is part of the Administration for Strategic Preparedness and Response within the US Department of Health and Human Services.
The option is part of Emergent's existing 10-year contract with BARDA for advanced development and procurement of Ebanga, with a maximum value of $704 million, the company said.
Shares of Emergent BioSolutions fell past 5% in recent trading.
Price: 9.33, Change: -0.55, Percent Change: -5.57
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.